Literature DB >> 16291942

Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Clifford W Shults1, Edward Rockenstein, Leslie Crews, Anthony Adame, Michael Mante, Gabriel Larrea, Makoto Hashimoto, David Song, Takeshi Iwatsubo, Kyoko Tsuboi, Eliezer Masliah.   

Abstract

Multiple system atrophy (MSA) is a progressive, neurodegenerative disease characterized by parkinsonism, ataxia, autonomic dysfunction, and accumulation of alpha-synuclein (alpha-syn) in oligodendrocytes. To better understand the mechanisms of neurodegeneration and the role of alpha-syn accumulation in oligodendrocytes in the pathogenesis of MSA, we generated transgenic mouse lines expressing human (h) alpha-syn under the control of the murine myelin basic protein promoter. Transgenic mice expressing high levels of halpha-syn displayed severe neurological alterations and died prematurely at 6 months of age. Furthermore, mice developed progressive accumulation of halpha-syn-immunoreactive inclusions in oligodendrocytes along the axonal tracts in the brainstem, basal ganglia, cerebellum, corpus callosum, and neocortex. The inclusions also reacted with antibodies against phospho-serine (129) halpha-syn and ubiquitin, and halpha-syn was found in the detergent-insoluble fraction. In high-expresser lines, the white matter tracts displayed intense astrogliosis, myelin pallor, and decreased neurofilament immunostaining. Accumulation of halpha-syn in oligodendrocytes also leads to prominent neurodegenerative changes in the neocortex with decreased dendritic density and to loss of dopaminergic fibers in the basal ganglia. The oligodendrocytic inclusions were composed of fibrils and accompanied by mitochondrial alterations and disruption of the myelin lamina in the axons. Together, these studies support the contention that accumulation of alpha-syn in oligodendrocytes promotes neurodegeneration and recapitulates several of the key functional and neuropathological features of MSA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291942      PMCID: PMC6725840          DOI: 10.1523/JNEUROSCI.3527-05.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  110 in total

1.  Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model.

Authors:  Nadia Stefanova; Biljana Georgievska; Håkan Eriksson; Werner Poewe; Gregor K Wenning
Journal:  Neurotox Res       Date:  2011-12-08       Impact factor: 3.911

Review 2.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

3.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

4.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

5.  Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.

Authors:  Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

6.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

Review 7.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

Review 8.  Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study.

Authors:  Wolfgang Singer; Phillip A Low
Journal:  Clin Auton Res       Date:  2015-03-13       Impact factor: 4.435

9.  Bladder dysfunction in a transgenic mouse model of multiple system atrophy.

Authors:  Mathieu Boudes; Pieter Uvin; Silvia Pinto; Thomas Voets; Clare J Fowler; Gregor K Wenning; Dirk De Ridder; Nadia Stefanova
Journal:  Mov Disord       Date:  2013-02-20       Impact factor: 10.338

10.  p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy.

Authors:  Yun Ju C Song; Ditte M S Lundvig; Yue Huang; Wei Ping Gai; Peter C Blumbergs; Peter Højrup; Daniel Otzen; Glenda M Halliday; Poul H Jensen
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.